Novel agents for advanced pancreatic cancer
Metrics: PDF 1322 views | HTML 2410 views | ?
Akintunde Akinleye1, Chaitanya Iragavarapu1, Muhammad Furqan2, Shundong Cang3, Delong Liu4
1Division of Hematology/Oncology, Department of Medicine, New York Medical College, Valhalla, New York, United States
2Division of Hematology/Oncology, Department of Medicine, University of Iowa, Iowa City, Iowa, United States
3Department of Oncology, Henan Province People’s Hospital, Zhengzhou University, Zhengzhou, China
4Department of Oncology, Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
Delong Liu, e-mail: firstname.lastname@example.org
Keywords: pancreatic cancer, IGF-1R
Received: February 27, 2015 Accepted: May 20, 2015 Published: June 03, 2015
Pancreatic cancer is relatively insensitive to conventional chemotherapy. Therefore, novel agents targeting dysregulated pathways (MAPK/ERK, EGFR, TGF-β, HEDGEHOG, NOTCH, IGF, PARP, PI3K/AKT, RAS, and Src) are being explored in clinical trials as monotherapy or in combination with cytotoxic chemotherapy. This review summarizes the most recent advances with the targeted therapies in the treatment of patients with advanced pancreatic cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.